{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:08:07Z","timestamp":1784113687949,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004087","name":"Shizuoka University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23nk0101111"],"award-info":[{"award-number":["JP23nk0101111"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmpk.2026.101539","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:20:01Z","timestamp":1776234001000},"page":"101539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Differences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisostere"],"prefix":"10.1016","volume":"69","author":[{"given":"Minami","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5948-4111","authenticated-orcid":false,"given":"Ayato","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Nakayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3767-7686","authenticated-orcid":false,"given":"Masahiro","family":"Hiratsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yamanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2027-2017","authenticated-orcid":false,"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2026.101539_bib1","series-title":"Cytochrome P450: structure, mechanism, and biochemistry","first-page":"523","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"2015"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s00204-024-03710-9","article-title":"Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes","volume":"98","author":"Rendic","year":"2024","journal-title":"Arch Toxicol"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101539_bib3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.drudis.2016.11.018","article-title":"Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design","volume":"22","author":"Brink","year":"2017","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jat.3277","article-title":"Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs","volume":"36","author":"Gomez-Lechon","year":"2016","journal-title":"J Appl Toxicol"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101539_bib5","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.113.056267","article-title":"High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101539_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2174\/138920021131400114","article-title":"Mechanism-based inhibition of CYP450: an indicator of drug-induced hepatotoxicity","volume":"14","author":"Feng","year":"2013","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.dmpk.2026.101539_bib7","article-title":"Cytochrome P450 inhibition correlates with hepatotoxicity of pesticides: analysis using repeated-dose toxicity data in rats","author":"Shibata","year":"2025","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101539_bib8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2131\/jts.47.359","article-title":"Involvement of the CYP1A1 inhibition-mediated activation of aryl hydrocarbon receptor in drug-induced hepatotoxicity","volume":"47","author":"Yoda","year":"2022","journal-title":"J Toxicol Sci"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101539_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2131\/jts.46.167","article-title":"Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury","volume":"46","author":"Shimizu","year":"2021","journal-title":"J Toxicol Sci"},{"issue":"12","key":"10.1016\/j.dmpk.2026.101539_bib10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/00498250701658312","article-title":"Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro","volume":"37","author":"Turpeinen","year":"2007","journal-title":"Xenobiotica"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmpk.2026.101539_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tox.2016.11.014","article-title":"Comparison of xenobiotic-metabolising human, porcine, rodent, and piscine cytochrome P450","volume":"375","author":"Burkina","year":"2017","journal-title":"Toxicology"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.117.079848","article-title":"A decade in the MIST: learnings from investigations of drug metabolites in drug development under the \"Metabolites in Safety Testing\" regulatory guidance","volume":"46","author":"Schadt","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2026.101539_bib14","series-title":"Services USDoHaH","article-title":"Safety testing of drug metabolites guidance for industry","year":"2020"},{"key":"10.1016\/j.dmpk.2026.101539_bib15","series-title":"ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals","year":"2009"},{"issue":"9","key":"10.1016\/j.dmpk.2026.101539_bib16","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1007\/s11095-013-1007-6","article-title":"Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis","volume":"30","author":"McGill","year":"2013","journal-title":"Pharm Res"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101539_bib17","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/jm00349a001","article-title":"Metabolic activation and drug toxicity","volume":"25","author":"Nelson","year":"1982","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.dmpk.2026.101539_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1067\/mcp.2000.104736","article-title":"Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation","volume":"67","author":"Manyike","year":"2000","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101539_bib19","first-page":"1557","article-title":"Alcohol-mediated increases in acetaminophen hepatotoxicity: role of CYP2E and CYP3A","volume":"55","author":"Sinclair","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2026.101539_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/00498250802512830","article-title":"Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes","volume":"39","author":"Laine","year":"2009","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101539_bib21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2131\/jts.45.245","article-title":"Enhancement of acetaminophen-induced chronic hepatotoxicity in spontaneously diabetic torii (SDT) rats","volume":"45","author":"Kondo","year":"2020","journal-title":"J Toxicol Sci"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101539_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2131\/jts.37.911","article-title":"Enhancement of acetaminophen-induced chronic hepatotoxicity in restricted fed rats: a nonclinical approach to acetaminophen-induced chronic hepatotoxicity in susceptible patients","volume":"37","author":"Kondo","year":"2012","journal-title":"J Toxicol Sci"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101539_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1039\/cs9790800563","article-title":"Isosterism and molecular modification in drug design","volume":"8","author":"Thornber","year":"1979","journal-title":"Chem Soc Rev"},{"issue":"48","key":"10.1016\/j.dmpk.2026.101539_bib24","doi-asserted-by":"crossref","first-page":"21848","DOI":"10.1021\/jacs.2c09733","article-title":"Practical and facile access to Bicyclo[3.1.1]heptanes: potent bioisosteres of meta-substituted benzenes","volume":"144","author":"Iida","year":"2022","journal-title":"J Am Chem Soc"},{"issue":"49","key":"10.1016\/j.dmpk.2026.101539_bib25","doi-asserted-by":"crossref","first-page":"17791","DOI":"10.1021\/jacs.7b11865","article-title":"Radical multicomponent carboamination of [1.1.1]Propellane","volume":"139","author":"Kanazawa","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101539_bib26","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1021\/jm300094u","article-title":"Application of the Bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active \u03b3-Secretase inhibitor","volume":"55","author":"Stepan","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.dmpk.2026.101539_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.113510","article-title":"Development of a strategy to identify and evaluate direct and indirect activators of constitutive androstane receptor in rats","volume":"170","author":"Sato","year":"2022","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101539_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/00498254.2024.2312505","article-title":"Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury","volume":"54","author":"Kaito","year":"2024","journal-title":"Xenobiotica"},{"key":"10.1016\/j.dmpk.2026.101539_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2025.115566","article-title":"Utility of in vitro assay data in read-across prediction of nongenotoxic carcinogenicity of pesticides for cytotoxicity-related rat tumors","volume":"202","author":"Mizuno","year":"2025","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.dmpk.2026.101539_bib30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/0006-2952(87)90412-6","article-title":"Species differences in the hepatotoxicity of paracetamol are due to differences in the rate of conversion to its cytotoxic metabolite","volume":"36","author":"Tee","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101539_bib31","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.tiv.2008.02.001","article-title":"Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes","volume":"22","author":"Jemnitz","year":"2008","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.dmpk.2026.101539_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114854","article-title":"Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity","volume":"388","author":"Watanabe","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmpk.2026.101539_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2025.106075","article-title":"Association between drug-induced heart failure and CYP1A1, CYP1B1, and CYP3A4 inhibition: utility of cytochrome P450 inhibition assay for evaluating cardiotoxicity of drug candidates","volume":"107","author":"Kaito","year":"2025","journal-title":"Toxicol Vitro"},{"key":"10.1016\/j.dmpk.2026.101539_bib34","series-title":"Gaussian Inc 16, revision A. 03","author":"Frisch","year":"2016"},{"key":"10.1016\/j.dmpk.2026.101539_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.procs.2019.08.181","article-title":"Structure of biomolecules through molecular dynamics simulations","volume":"156","author":"Arnittali","year":"2019","journal-title":"Procedia Comput Sci"},{"issue":"7","key":"10.1016\/j.dmpk.2026.101539_bib36","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib37","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1021\/jm00032a021","article-title":"Preferred orientations in the binding of 4'-Hydroxyacetanilide (Acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies","volume":"37","author":"Myers","year":"1994","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.dmpk.2026.101539_bib38","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1021\/tx7000702","article-title":"Cooperative binding of Acetaminophen and caffeine within the P450 3A4 active site","volume":"20","author":"Cameron","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.dmpk.2026.101539_bib39","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1021\/acsmedchemlett.7b00018","article-title":"Toward resolving the resveratrol conundrum: synthesis and in vivo. Pharmacokinetic evaluation of BCP\u2212Resveratrol","volume":"8","author":"Goh","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.dmpk.2026.101539_bib40","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/03602532.2011.624103","article-title":"Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order","volume":"43","author":"Yamazoe","year":"2012","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmpk.2026.101539_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2021.100413","article-title":"Refined CYP2E1\u2217 template\u2217\u2217 system to decipher the ligand-interactions","volume":"41","author":"Yamazoe","year":"2021","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmpk.2026.101539_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.dmpk.2019.05.003","article-title":"Solving the interactions of steroidal ligands with CYP3A4 using a grid-base template system","volume":"34","author":"Goto","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101539_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.dmpk.2017.05.004","article-title":"Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 2: solving substrate interactions of CYP1A2 with non-PAH substrates on the template system","volume":"32","author":"Yamazoe","year":"2017","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2026.101539_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.dmpk.2016.07.005","article-title":"Prediction of regioselectivity and preferred order of metabolisms on CYP1A2-mediated reactions. Part 1. Focusing on polycyclic arenes and the related chemicals","volume":"31","author":"Yamazoe","year":"2016","journal-title":"Drug Metabol Pharmacokinet"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672600025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S134743672600025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:52:27Z","timestamp":1784112747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S134743672600025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S134743672600025X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101539","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in reactive metabolite formation and cytochrome P450 binding between acetaminophen and its bicyclo[1.1.1]pentane bioisostere","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2026.101539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101539"}}